DiviTum® Included in New U.S. Cancer Study
Biovica and the SWOG Cancer Research Network have entered into an agreement to study the clinical benefit of DiviTum® using patient blood samples from SWOG 0226, a clinical trial that showed that women with metastatic hormone receptor-positive breast cancer live longer when they receive a combination of two anti-estrogen drugs.Under the agreement, the DiviTum® blood assay will be used to analyze blood samples taken from participants in S0226, which between 2004 and 2009 enrolled 707 postmenopausal women with metastatic breast cancer at 73 hospitals, clinics, and cancer centers across the